CELL AND GENE THERAPY

Enabling the Future of Cell & Gene Therapies through Non Proprietary Patient-Owned Data Collection

March 16, 2021

herapies through Non Proprietary
Cell and gene therapies have emerged as a new treatment paradigm, and with them has come the potential
to alter the course of many rare diseases. In many cases, there is an opportunity to correct the underlying
dysfunction with a one-time administration of a therapy and provide either a functional cure or a substantial
improvement in health outcomes. In other cases, long term symptom relief will be the primary therapeutic
objective. Some of these indications may require more than one dose to achieve continued symptom relief
and scientists and companies are working on technologies that will enable the use of a repeat dose.

Spotlight

Maverix Biomics

Maverix Biomics brings together decades of experience and expertise in biologic research, bioinformatics, and enterprise application software development from many of today’s leading research institutions and technology companies.

OTHER WHITEPAPERS
news image

IoT To The Rescue For Biotech & Pharma Manufacturing

whitePaper | April 7, 2020

The Internet of Things (IoT) could not be timelier for biotech/pharma. With fierce cost pressures, the push for value-based outcomes, and the need for flexible manufacturing solutions, the IoT is the much-needed shot in the arm to bring about transformational change. Sensors, actuators, and devices (“things”) embedded in production equipment and networked through computer systems can generate an enormous amount of data. The data can be mined for insights and opportunities to drive production efficiency, automate monitoring and controlling functions, and enable flexible manufacturing systems.

Read More
news image

Next Generation Therapies and related Life Sciences topics

whitePaper | January 16, 2022

All gene therapies insert engineered DNA/RNA into living cells to make or modify new proteins

Read More
news image

A digital ecosystem for Clinical Trails

whitePaper | July 30, 2021

Clinical trials are complex, lengthy, and resource-inefficient. The clinical research industry is responsible for the delivery of medical solutions to society by systematically evaluating their safety and efficacy in humans during so-called clinical trials. As exemplified by the COVID-19 pandemic, a steady and efficient influx of vaccines, therapeutics, and other innovative medical solutions is critical for meeting society’s current and future medical needs. Unfortunately, the industry faces several persistent issues that make clinical trial operations overly complex, lengthy, and resource-inefficient.

Read More
news image

WHO considerations on Regulatory Convergence of Cell and Gene Therapy Products

whitePaper | December 16, 2021

Use of cells, tissues, and gene therapy products for the treatment of diseases or 72 physiological conditions has become of wide interest due to their potential to address serious 73 unmet medical needs.

Read More
news image

BIOPHARMACEUTICAL INDUSTRY AND INTERRELATED BIOTECHNOLOGY ORGANIZATIONS

whitePaper | November 21, 2019

Our Accounting and Finance team has published an overview of the accounting and finance challenges facing the Biopharmaceutical industry and interrelated Biotechnology organizations.

Read More
news image

Covid-19 Vaccine Distribution System

whitePaper | April 14, 2021

Delivering Covid-19 vaccines to 7.8 billion people is a daunting challenge that will stretch supply chains past their limits. Even if all the needed doses were ready today, vaccine manufacturers still must find solutions to deliver multiple doses of those vaccines to most people on the planet. To read more, please download this free white paper.

Read More

Spotlight

Maverix Biomics

Maverix Biomics brings together decades of experience and expertise in biologic research, bioinformatics, and enterprise application software development from many of today’s leading research institutions and technology companies.

Events